The European Medicines Agency (EMA) Has Approved an Additional Subcutaneous Administration Option for TAKHZYRO ® (lanadelumab) for Patients Aged 12 Years and Above with Recurrent Attacks of Hereditary
Source link
The European Medicines Agency (EMA) Has Approved an Additional Subcutaneous Administration Option for TAKHZYRO ® (lanadelumab) for Patients Aged 12 Years and Above with Recurrent Attacks of Hereditary
By Bella Hayes
